Viewing Study NCT05809895

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 2:08 PM

Ignite Modification Date: 2025-12-29 @ 5:59 PM

Study NCT ID: NCT05809895

Status: WITHDRAWN

Last Update Posted: 2023-07-24

First Post: 2023-03-30

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer

Sponsor: Novartis Pharmaceuticals

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module